Download MendeleyPromise and Challenge of beta-Lactone Electrophiles to Target Aspartate 12 of Mutant KRAS G12D .
Budai, B., Vaupel, A., Dickson, C.J., Beyer, K.S., Guthy, D.A., Ostermann, N., McGregor, L.M., De Kanter, R., Weiss, A., Linder, M., Sager, E., Bomio-Confaglia, C., Proctor, R., Leblanc, C., Yuan, J., Cotesta, S., Wilcken, R., Danilack, A.D., Garcia, F., Rogemoser, P., Kazic-Legueux, M., Zhang, Z., Zheng, Q., Shokat, K.M., Brachmann, S.M., Ehmke, V.(2025) J Med Chem 68: 15050-15064
- PubMed: 40635203
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01214
- Primary Citation of Related Structures:
9QPZ, 9QQ0, 9QQ1 - PubMed Abstract:
The clinical success of covalent KRAS G12C inhibition prompts further expansion of the concept to target non-cysteine oncogenic mutation sites as in KRAS G12D . This endeavor was hampered by the lack of suitable electrophiles for the selective, covalent engagement of aspartate. Thanks to the recent discovery of β-lactone-bearing covalent inhibitors, new opportunities are emerging. Based on X-ray crystallographic insights and quantum chemical calculations, we herein describe the elucidation of structure-activity and -stability correlations to advance such electrophiles for drug discovery. Guided by predictions of transition state barrier heights for the attack of aspartate 12 at the β-lactone electrophile and structure-based design, we generated substituted β-lactones aiming to balance specific reactivity and chemical and metabolic stability. Our optimization strategy is driven by MS-based and cellular covalent target occupancy assays and PD marker analysis, proteome-wide profiling, and synthetic chemistry. With this work, we aim to expand the use of β-lactones as chemoselective electrophiles in medicinal chemistry.
- Novartis BioMedical Research, 4056 Basel, Switzerland.
Organizational Affiliation:
